These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15454486)

  • 21. Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo.
    Triozzi PL; Aldrich W; Dombos C
    Melanoma Res; 2008 Dec; 18(6):420-30. PubMed ID: 18971787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role for thymic and splenic regulatory CD4+ T cells induced by donor dendritic cells in allograft tolerance by LF15-0195 treatment.
    Chiffoleau E; Bériou G; Dutartre P; Usal C; Soulillou JP; Cuturi MC
    J Immunol; 2002 May; 168(10):5058-69. PubMed ID: 11994458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic anti-tumor response induced with epitope-pulsed fibroblasts genetically engineered for B7.1 expression and IFN-gamma secretion.
    Kim TS; Chung SW; Kim SH; Kang SN; Kang BY
    Int J Cancer; 2000 Aug; 87(3):427-33. PubMed ID: 10897050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.
    Katayama R; Huelsmeyer MK; Marr AK; Kurzman ID; Thamm DH; Vail DM
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):25-33. PubMed ID: 15108021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. UVB-irradiated dendritic cells are impaired in their APC function and tolerize primed Th1 cells but not naive CD4+ T cells.
    Denfeld RW; Hara H; Tesmann JP; Martin S; Simon JC
    J Leukoc Biol; 2001 Apr; 69(4):548-54. PubMed ID: 11310840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.
    Herrera OB; Brett S; Lechler RI
    Vaccine; 2002 Dec; 21(3-4):231-42. PubMed ID: 12450698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules.
    Sexton A; Whitney PG; Chong SF; Zelikin AN; Johnston AP; De Rose R; Brooks AG; Caruso F; Kent SJ
    ACS Nano; 2009 Nov; 3(11):3391-400. PubMed ID: 19824668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ T lymphocytes.
    Joffre O; Gorsse N; Romagnoli P; Hudrisier D; van Meerwijk JP
    Blood; 2004 Jun; 103(11):4216-21. PubMed ID: 14976053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism.
    Patel JM; Cui Z; Wen ZF; Dinh CT; Hu HM
    J Immunother Cancer; 2019 Nov; 7(1):311. PubMed ID: 31747946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acquisition of MHC:peptide complexes by mouse CD4+ T cells may play a role in T-cell-mediated immunoregulation.
    Tsang JY; Chai JG; Lechler R
    Transplant Proc; 2002 Nov; 34(7):2849-50. PubMed ID: 12431632
    [No Abstract]   [Full Text] [Related]  

  • 31. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
    Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
    Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A CCR4 antagonist enhances DC activation and homing to the regional lymph node and shows potent vaccine adjuvant activity through the inhibition of regulatory T-cell recruitment.
    Yamamoto S; Matsuo K; Nagakubo D; Higashiyama S; Nishiwaki K; Oiso N; Kawada A; Yoshie O; Nakayama T
    J Pharmacol Sci; 2018 Mar; 136(3):165-171. PubMed ID: 29519579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of T-effector function by imatinib at the level of cytokine secretion.
    Leder C; Ortler S; Seggewiss R; Einsele H; Wiendl H
    Exp Hematol; 2007 Aug; 35(8):1266-71. PubMed ID: 17560008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerance induction with gene-modified stem cells and immune-preserving conditioning in primed mice: restricting antigen to differentiated antigen-presenting cells permits efficacy.
    Coleman MA; Bridge JA; Lane SW; Dixon CM; Hill GR; Wells JW; Thomas R; Steptoe RJ
    Blood; 2013 Feb; 121(6):1049-58. PubMed ID: 23233664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of Imatinib mesylate on the development of dendritic cells derived from bone marrow mononuclear cells of patients with chronic myeloid leukemia].
    Zheng SE; Jin J; Tong XM
    Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(32):2252-5. PubMed ID: 17064569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.
    Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK
    Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Classical dendritic cells are required for dietary antigen-mediated induction of peripheral T(reg) cells and tolerance.
    Esterházy D; Loschko J; London M; Jove V; Oliveira TY; Mucida D
    Nat Immunol; 2016 May; 17(5):545-55. PubMed ID: 27019226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia.
    Zeng Y; Graner MW; Feng H; Li G; Katsanis E
    Int J Cancer; 2004 Jun; 110(2):251-9. PubMed ID: 15069690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo.
    Dietz AB; Souan L; Knutson GJ; Bulur PA; Litzow MR; Vuk-Pavlovic S
    Blood; 2004 Aug; 104(4):1094-9. PubMed ID: 15100154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming.
    Schlecht G; Loucka J; Najar H; Sebo P; Leclerc C
    J Immunol; 2004 Nov; 173(10):6089-97. PubMed ID: 15528345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.